Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)

INTRODUCTION: The prognosis of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is dismal and conventional chemotherapy treatment delivers limited survival improvement. Immunotherapy may complement our current treatment strategies. We previously demonstrated that the combination of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Sai Ping, van ’t Land, Freek R, van der Burg, Sjoerd H, Homs, Marjolein Y V, Lolkema, Martijn P, Aerts, Joachim G J V, van Eijck, Casper H J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207896/
https://www.ncbi.nlm.nih.gov/pubmed/35710239
http://dx.doi.org/10.1136/bmjopen-2021-060431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207896/
https://www.ncbi.nlm.nih.gov/pubmed/35710239
http://dx.doi.org/10.1136/bmjopen-2021-060431

Ejemplares similares